FOLD - Today's Research Reports on Trending Tickers: Amarin and Amicus Therapeutics
NEW YORK, NY / ACCESSWIRE / September 27, 2018 / U.S. markets fell sharply Wednesday after the Federal Reserve raised interest rates and indicated another increase would be coming in December. The Dow Jones Industrial Average dropped 0.4 percent to close at 26,385.28, while the S&P 500 Index declined 0.33 percent to close at 2,905.97. The Nasdaq Composite Index decreased 0.21 percent to close at 7,990.37.
“It was virtually a foregone conclusion, and that may cause some investors to scratch their heads a bit given all the uncertainty in the market, with trade barbs flying, an unstable housing market, and ballooning federal debt,” according to Mike Loewengart, vice president of investment strategy at E-Trade Financial Corp. “But the Fed needs to build up its toolbox to address a variety of economic conditions, which makes getting back to a normalized rate environment so important. They will drive towards that end state until the economic landscape is dramatically different,” Loewengart added.
RDI Initiates Coverage on:
Amarin Corporation plc
https://rdinvesting.com/news/?ticker=AMRN
Amicus Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=FOLD
Amarin’s stock jumped 3.46% Wednesday, to close the day at $13.45. The stock recorded a trading volume of 41,779,113 shares, which was above its three months average volume of 7,544,371 shares. In the last year, Amarin's shares have traded in a range of 2.35 - 14.64. The share price has gained 472.34% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $3.54 is above its 200-day moving average of $3.18. Shares of Amarin have gained roughly 385.56 percent in the past month and are up 235.41 percent year-to-date.
Access RDI's Amarin Corporation plc Research Report at:
https://rdinvesting.com/news/?ticker=AMRN
On Wednesday, shares of Amicus Therapeutics recorded a trading volume of 1,836,505 shares, which was below the three months average volume of 2,086,926 shares. The stock ended the day 3.28% higher at $12.59. The share price has fallen 28.55% from its 52 week high with a 52 week trading range of 11.57 - 17.62. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $13.06 is below its 200-day moving average of $14.62. Shares of Amicus Therapeutics have fallen roughly 3 percent in the past month and are down 12.51 percent year-to-date.
Access RDI's Amicus Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FOLD
Our Actionable Research on Amarin Corporation plc (NASDAQ :AMRN) and Amicus Therapeutics, Inc. (NASDAQ :FOLD) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com